Trials / Conditions / Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome With Diarrhea

51 registered clinical trials studyying Irritable Bowel Syndrome With Diarrhea — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Efficacy and Safety of FMT for the Treatment of IBS-D and Mental Health Comorbidity in Young Adults NCT06297421	Shenzhen Hospital of Southern Medical University	Phase 2
Completed	The Effect of Dietary Supplementation on Intestinal Barrier Function in IBS-D NCT06543498	Dr Anthony Hobson	N/A
Recruiting	B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Bios NCT06612411	Jinling Hospital, China	EARLY_Phase 1
Recruiting	A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D NCT06247046	Guangzhou Zhiyi Biotechnology Co., Ltd.	Phase 3
Enrolling By Invitation	Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel S NCT07103772	Universidad Autonoma de Nuevo Leon	N/A
Completed	Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1) NCT06432569	University of Padova	N/A
Terminated	Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS- NCT06153420	CinPhloro Pharma, LLC	Phase 2
Completed	Safety and Efficacy of a Probiotic Supplement in IBS-D NCT05754177	The Archer-Daniels-Midland Company	N/A
Completed	Self- Administered Acupressure for Diarrhea Predominant Irritable Bowel Syndrome NCT05702255	Alexandria University	N/A
Unknown	Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With Diarrhea NCT05719896	Centre of Clinical Pharmacology, Hanoi Medical University	Phase 2
Completed	To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea NCT05867550	Bahria University	Phase 4
Unknown	Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome NCT05646186	Istanbul Medipol University Hospital	N/A
Completed	Probiotics as Adjuvant Therapy in the Management of Irritable Bowel Syndrome NCT05523427	University of Mosul	N/A
Withdrawn	Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Withou NCT05453916	Sadat City University	Phase 1 / Phase 2
Completed	Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treate NCT05339243	Vedic Lifesciences Pvt. Ltd.	N/A
Completed	Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM) NCT05130047	Michael Camilleri, MD	Phase 2
Completed	GI Permeability Change in Response to Aquamin® NCT04855799	James Varani	Phase 2
Unknown	Study on the Molecular Mechanism of Diarrhea-predominant Irritable Bowel Syndrome With Anxiety and Depression NCT05311293	Tang-Du Hospital	—
Completed	To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel Syndrome NCT04950296	Vedic Lifesciences Pvt. Ltd.	N/A
Completed	The Role of Fiber in the Prevention and Treatment of Fecal Incontinence NCT04806386	Massachusetts General Hospital	N/A
Unknown	Intestinal Permeability and Intestinal Microbiota in Irritable Bowel Syndrome NCT05379036	I.M. Sechenov First Moscow State Medical University	Phase 4
Completed	Faecal Microbiota Transplantation in Irritable Bowel Syndrome NCT04899869	Thomayer University Hospital	N/A
Completed	The Effects of Carbohydrates in Irritable Bowel Syndrome NCT04830410	Sahlgrenska University Hospital	N/A
Completed	Efficacy and Safety of Rifaximin With NAC in IBS-D NCT04557215	Cedars-Sinai Medical Center	Phase 1 / Phase 2
Completed	Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1 NCT05277428	Amorepacific Corporation	N/A
Completed	Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IB NCT04492787	Tasly Pharmaceutical Group Co., Ltd	Phase 2
Withdrawn	A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS NCT04214470	ProgenaBiome	—
Completed	Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarr NCT03729271	University of Michigan	Phase 4
Completed	A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Dia NCT04129619	OrphoMed, Inc.	Phase 2
Completed	Multi Strain Probiotic Preparation in Patients With Irritable Bowel Syndrome NCT04662957	Children's Memorial Health Institute, Poland	N/A
Completed	A Mediterranean Approach to Low FODMAP Diet (MED-LFD) for Managing IBS Symptoms NCT03997708	Attikon Hospital	N/A
Completed	Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D) NCT04053790	Hospital General de Mexico	Phase 4
Completed	Interest of Pan Capsule in Symptomatic Patients Suspected of Irritable Bowel Syndrome Requiring Colonoscopy NCT03806959	Hospital Avicenne	N/A
Completed	Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Pre NCT03557788	National University Hospital, Singapore	Phase 4
Completed	Eluxadoline Bile Acid Malabsorption (BAM) Study NCT03441581	Allergan	Phase 4
Completed	Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients NCT04484467	Federal Stare Budgetary Scientific Institution, Mental Health Research Center	N/A
Completed	Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption NCT03270085	Mayo Clinic	Phase 2
Unknown	Effect of FODMAPs on Mucosal Inflammation in IBS Patients NCT03221790	Queen's University	N/A
Completed	FODMAP Reintroduction in Irritable Bowel Syndrome NCT03245645	University of California, Los Angeles	N/A
Completed	Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate NCT02959983	Allergan	Phase 4
Completed	Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Table NCT02757105	RedHill Biopharma Limited	Phase 2
Completed	The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome NCT02431533	Pharmabiotix Inc	N/A
Withdrawn	12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) NCT02320318	Menarini Group	Phase 3
Completed	12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) NCT02107196	Menarini Group	Phase 3
Terminated	52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) NCT02120027	Menarini Group	Phase 3
Completed	Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea NCT02822118	Xiyuan Hospital of China Academy of Chinese Medical Sciences	Phase 1 / Phase 2
Completed	Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study NCT01543178	Bausch Health Americas, Inc.	Phase 3
Completed	Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D) NCT01303224	Menarini Group	Phase 2
Completed	Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea NCT01177410	Bausch Health Americas, Inc.	Phase 2
Completed	Post-Infectious Irritable Bowel Syndrome (PI-IBS) NCT01497847	KU Leuven	—
Completed	Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) NCT00552565	AGI Therapeutics, Inc.	Phase 3